NASDAQ:CYADCELYAD SA/ADR Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CELYAD SA/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.86 +0.18 (+1.54 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$11.86Now: $11.86▼$12.4050-Day Range$8.39MA: $9.24▼$12.4752-Week Range$4.10Now: $11.86▼$20.42Volume33,662 shsAverage Volume29,307 shsMarket Capitalization$165.33 millionP/E RatioN/ADividend YieldN/ABeta1.39 ProfileAnalyst RatingsAdvanced ChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCELYAD SA/ADR has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.33, CELYAD SA/ADR has a potential upside of 130.5% from its current price of $11.86.Amount of Analyst CoverageCELYAD SA/ADR has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesCELYAD SA/ADR has received 261 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCELYAD SA/ADR has received 221 “underperform” votes. (Add your “underperform” vote.)Community SentimentCELYAD SA/ADR has received 54.15% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CELYAD SA/ADR and other stocks. Vote “Outperform” if you believe CYAD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCELYAD SA/ADR does not currently pay a dividend.Dividend GrowthCELYAD SA/ADR does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CELYAD SA/ADR insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 7.59% of the stock of CELYAD SA/ADR is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CELYAD SA/ADR are expected to grow in the coming year, from ($2.58) to ($2.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CELYAD SA/ADR is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CELYAD SA/ADR is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCELYAD SA/ADR has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.37 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYAD Previous Symbol CUSIPN/A CIK1637890 Webwww.celyad.com Phone321-039-4100Debt Debt-to-Equity Ratio0.07 Current Ratio3.59 Quick Ratio3.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales16,532.84 Cash FlowN/A Price / Cash FlowN/A Book Value$3.67 per share Price / Book3.23Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares13,940,000Market Cap$165.33 million Next Earnings DateN/A OptionableNot Optionable NASDAQ:CYAD Rates by TradingView Receive CYAD News and Ratings via Email Sign-up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter. CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions How has CELYAD SA/ADR's stock been impacted by COVID-19 (Coronavirus)? CELYAD SA/ADR's stock was trading at $7.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYAD stock has increased by 51.1% and is now trading at $11.86. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of CELYAD SA/ADR? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CELYAD SA/ADR. What price target have analysts set for CYAD? 4 brokerages have issued 12-month price targets for CELYAD SA/ADR's shares. Their forecasts range from $20.00 to $37.00. On average, they anticipate CELYAD SA/ADR's share price to reach $27.33 in the next year. This suggests a possible upside of 130.5% from the stock's current price. View analysts' price targets for CELYAD SA/ADR. What are Wall Street analysts saying about CELYAD SA/ADR stock? Here are some recent quotes from research analysts about CELYAD SA/ADR stock: 1. According to Zacks Investment Research, "Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. " (3/31/2020) 2. HC Wainwright analysts commented, "Our $48 price target is based on our probability-adjusted revenue forecasts for CYAD-01 in r/r AML, and third-line metastatic for metastatic CRC. We use the net present value of our revenue forecast through 2027, apply a 25% POS for 20% POS for 20% POS for 4x price/sales multiple. We include our year-end 2019 estimated fully diluted net cash of $1.20/share (assuming €1.00 = $1.11) to arrive at our price target. Our P/S multiple of 4x is in-line with Celyad’s peers that range between 2-5x." (8/26/2019) 3. William Blair analysts commented, "We believe that the data readouts in the second half of the year will shed light into the clinical improvements with the Optimab process, allogeneic platform, and the impact of the preconditioning regimen at potentially clinically relevant doses with an eye toward selecting a Phase II (potentially registration enabling) study regimen in 2020. Celyad in June presented updated data from dose level 3 (3e9 cells given in three biweekly infusions) and initial data from cohort 10 (1e9 cells at a dense schedule of three CY AD-01 weekly infusions) of the THINK study at the European Hematology Association (EHA) 2019 meeting (EHA With CY AD-01 Dense Schedule and Preconditioning Regimens)." (8/23/2019) Has CELYAD SA/ADR been receiving favorable news coverage? News coverage about CYAD stock has been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CELYAD SA/ADR earned a news impact score of -2.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutCELYAD SA/ADR. Who are some of CELYAD SA/ADR's key competitors? Some companies that are related to CELYAD SA/ADR include Ardelyx (ARDX), Vanda Pharmaceuticals (VNDA), Trillium Therapeutics (TRIL), Sinovac Biotech (SVA), Morphic (MORF), Passage Bio (IMRA), Zafgen (ZFGN), Stemline Therapeutics (STML), Assembly Biosciences (ASMB), DiaMedica Therapeutics (DMCAF), Passage Bio (KROS), Athersys (ATHX), Syndax Pharmaceuticals (SNDX), Radius Health (RDUS) and Frequency Therapeutics (FREQ). View all competitors. What other stocks do shareholders of CELYAD SA/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other CELYAD SA/ADR investors own include GALAPAGOS NV/S (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Chromadex (CDXC), Intercept Pharmaceuticals (ICPT), bluebird bio (BLUE), AbbVie (ABBV), Potash Co. of Saskatchewan (POT), Ra Pharmaceuticals (RARX) and SCYNEXIS (SCYX). Who are CELYAD SA/ADR's key executives? CELYAD SA/ADR's management team includes the following people: Mr. Michel E. Lussier, Co-Founder & Chairman (Age 63)Mr. Filippo Joseph Petti, CEO & Interim CFODr. Jean-Pierre Latere, Chief Operating Officer (Age 44)Nicolas Van Hoecke, Director of Investor Relations & CommunicationsMr. Philippe Dechamps, Chief Legal Officer (Age 49) When did CELYAD SA/ADR IPO? (CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray acted as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers. What is CELYAD SA/ADR's stock symbol? CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD." Who are CELYAD SA/ADR's major shareholders? CELYAD SA/ADR's stock is owned by a number of retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (7.12%), Victory Capital Management Inc. (7.12%), Morgan Stanley (0.29%) and Wells Fargo & Company MN (0.05%). Which institutional investors are selling CELYAD SA/ADR stock? CYAD stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Victory Capital Management Inc., and Victory Capital Management Inc.. Which institutional investors are buying CELYAD SA/ADR stock? CYAD stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley. How do I buy shares of CELYAD SA/ADR? Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CELYAD SA/ADR's stock price today? One share of CYAD stock can currently be purchased for approximately $11.86. How big of a company is CELYAD SA/ADR? CELYAD SA/ADR has a market capitalization of $165.33 million and generates $10,000.00 in revenue each year. The company earns $-32,070,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis. What is CELYAD SA/ADR's official website? The official website for CELYAD SA/ADR is www.celyad.com. How can I contact CELYAD SA/ADR? CELYAD SA/ADR's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at 321-039-4100. This page was last updated on 6/4/2020 by MarketBeat.com Staff
